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Peroxisome proliferator-activated receptor a (PPARa) is a well-known therapeutic target for treating
hyperlipidemia. K-877 is a novel selective PPARa modulator (SPPARMa) that enhances PPARa tran-
scriptional activity with high selectivity and potency, resulting in reduced plasma lipid levels. This study
aimed to evaluate the effects of K-877 on hyperlipidemia in low-density lipoprotein receptor knockout
(Ldlr/) mice, a mouse model of atherosclerosis. We revealed that K-877 administration signiﬁcantly
decreased plasma triglyceride (TG) and total cholesterol (TC) levels and increased plasma high-density
lipoprotein cholesterol (HDL-C) levels in Ldlr/ mice. K-877 administration to Ldlr/ mice efﬁciently
increased the gene expression of PPARa and its target genes related to fatty acid oxidation in the liver and
small intestine. The same treatment signiﬁcantly increased ATP-binding cassette a1 gene expression in
the liver and small intestine and reduced Niemann Pick C1-like 1 gene expression in the small intestine,
suggesting that K-877 administration induced HDL-C production in the liver and small intestine and
reduced cholesterol absorption in the small intestine. In conclusion, K-877 administration had pro-
nounced effects on the liver and small intestine in Ldlr/mice. K-877 is an attractive PPARa-modulating
drug for treating hyperlipidemia that works equally well in both the liver and small intestine.
© 2017 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Peroxisome proliferator-activated receptors (PPARs) are mem-
bers of the nuclear receptor superfamily comprising three sub-
types: PPARa, PPARb/d, and PPARg. Upon ligand binding, PPARs
form heterodimers with the retinoid X receptor and interact withr Integrative Sleep Medicine
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d/4.0/).PPAR response elements to regulate target gene expression. PPARa
is ubiquitously expressed and is activated by hypolipidemic ﬁbrate-
class drugs (ﬁbrates). It controls lipid ﬂux in the liver bymodulating
fatty acid transport and b-oxidation and improves plasma lipid
proﬁles by decreasing TG and increasing HDL-C levels. Fibrates such
as gemﬁbrozil, bezaﬁbrate, and fenoﬁbrate (Feno) decrease plasma
TG levels and increase HDL-C levels in patients with hyperlipidemia
and type 2 diabetes and can prevent coronary heart disease and
stroke.1e5
Pharmaceutical approaches that aimed to affect cholesterol
metabolism target PPARa to treat or prevent the development of
cardiovascular disease, particularly atherosclerosis. The activation
of liver X receptor (LXR) by synthetic ligands increases HDL-C levels
and reverses cholesterol transport, resulting in reduced athero-
sclerotic plaque formation in mice. LXR activation upregulates thenese Pharmacological Society. This is an open access article under the CC BY-NC-ND
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(Abca)1, Abcg1, and Abcg5/g8. ABCA1 mediates the rate-controlling
step in HDL particle formation by promoting the efﬂux of choles-
terol and phospholipids to apolipoprotein a1 (ApoA-I).6,7 ABCA1
deﬁciency in Tangier disease is characterized by HDL deﬁciency,
high plasma TG levels, elevated tissue sterol levels, and premature
coronary atherosclerosis in some kindreds.8 Studies on tissue-
speciﬁc ablation have shown that hepatic and intestinal ABCA1
are responsible for approximately 70 and 30% of plasma HDL,
respectively.9,10 Cholesterol absorption has been extensively stud-
ied because of its signiﬁcant positive correlation with plasma
cholesterol levels and atherosclerosis.11e13 Cholesterol absorption
is deﬁned as the transport of dietary lipids from the intestinal
lumen across enterocytes into the plasma.12 The uptake of dietary
and biliary cholesterol occurs in the proximal small intestine.
Cholesterol uptake from the intestinal lumen by enterocytes is the
rate-limiting step in cholesterol absorption14, and studies have
demonstrated that NPC1L1, which is efﬁciently inhibited by ezeti-
mibe (a drug that speciﬁcally binds to the NPC1L1 protein), is
involved in this process.15e17
PPARa agonists reduce plasma LDL cholesterol levels in part by
decreasing cholesterol absorption.18e21 Feno suppresses Npc1l1
expression in the small intestine, thereby limiting cholesterol ab-
sorption at the level of cholesterol transport across the apical
membrane of enterocytes.22 However, ﬁbrates are weak agonists of
PPARa and have poor PPAR subtype selectivity and their efﬁcient
application requires high clinical doses. Therefore, a potent and
selective PPARa agonist is needed for treating patients with
metabolic syndrome. K-877 (pemaﬁbrate) is a novel selective
PPARamodulator (SPPARMa) that has been developed to maximize
receptor-mediated effects and diminish side effects and elicits.23,24
Here the effects of K-877 on lipid metabolism in LDL receptor
knockout (Ldlr/) mice, a mouse model of atherosclerosis, were
studied.
2. Materials and methods
2.1. Reagents
K-877, which is shown in Fig. 1, was kindly provided by Kowa Co.
Ltd, Tokyo Japan. Feno was purchased from SigmaeAldrich.
2.2. Animals
C57BL/6J (wild-type, WT) mice were obtained from CLEA Japan.
B6; 129S4-Pparatm1Gonz/J (Ppara/) and Ldlr/ mice were pur-
chased from Jackson Laboratory. Eight-week-old male WT andFig. 1. The structure of K-877.Ppara/ mice were fed a modest fat (MF) diet supplemented with
Feno or K-877 for 1 week. Eight-week-old male Ldlr/ mice were
fed an MF diet supplemented with K-877 for 1 week. All animal
husbandry procedures and experiments were compliant with the
University of Tsukuba's Regulations for Animal Experiments and
were approved by the Animal Experiment Committee at the Uni-
versity of Tsukuba.
2.3. Metabolic measurements
Plasma levels of TG, non-esteriﬁed fatty acid (NEFA), TC, HDL-C,
aspartate aminotransferase, alanine aminotransferase, and intesti-
nal TC were measured as previously described.25
2.4. Fecal cholesterol output
Fecal cholesterol outputs were measured as previously
described.26,27 Brieﬂy, mice were individually housed for fecal
collection. The feces were dried, weighed, and crushed into powder.
Fecal cholesterol was extracted from powdered feces with a chlo-
roform/methanol mixture (2:1 vol/vol).27
2.5. Postprandial TG response
Mice were starved for 16 h; this was followed by the oral
administration of 200 ml of olive oil.28 Blood samples were collected
at 0, 3, 6, and 9 h post administration.
2.6. Determination of plasma LPL activity
Mice were injected with 100 U/kg body weight of heparin (Novo
Heparin, Mochida Pharmaceutical Co., Ltd) via the tail veins. Blood
samples were collected at 20 min post administration. Plasma LPL
activity was determined using an LPL activity assay kit (Roar
Biochemical, Inc) according to the manufacturer's instructions.
2.7. Gene expression analysis
Total RNA from tissues was extracted using TRIzol reagent
(Invitrogen). Prior to real-time PCR analysis, total RNAwas reversed
transcribed into cDNA using a reverse transcriptase, according to
the manufacturer's instructions (Invitrogen). Real-time PCR was
performed using an ABI Prism 7300 system (ABI) with SYBR Green
Master Mix (Roche).29 Primer sequences are listed in Table 1. The
expression levels of mRNAwere normalized to those of Cyclophilin.
2.8. Statistical analyses
Comparisons of treatment groups were made using unpaired
Student's t-tests or TukeyeKramer post hoc tests, and differences
were considered signiﬁcant when p < 0.05. All data are expressed
as mean ± standard error of the mean.
3. Results
3.1. K-877 reduced plasma TG and TC levels and increased plasma
HDL-C levels in Ldlr/ mice
To determine the effects of K-877 on lipid metabolism, Ldlr/
micewere fedwith anMF diet supplementedwith 0.001% K-877 for
1 week. The dose of K-877 was decided according to a previous
report.30 K-877 administration signiﬁcantly reduced plasma TG
levels but did not change plasma NEFA levels (Fig. 2A). K-877
administration signiﬁcantly reduced plasma TC levels and
increased HDL-C levels in Ldlr/ mice (Fig. 2A). Thus, these
K. Takei et al. / Journal of Pharmacological Sciences 133 (2017) 214e222216ﬁndings indicate that the ratio of plasma HDL-C/TC levels was
higher with K-877 administration than that with no administration,
suggesting that K-877 has anti-atherogenic effects. To check plasma
TG metabolism by K-877, we studied the postprandial TG response
in these mice. K-877-treated Ldlr/ mice were signiﬁcantly lower
than non-treated- Ldlr/mice during this test (Fig. 2B), suggesting
an increase in TG clearance in K-877-treated Ldlr/ mice.
3.2. K-877 regulates gene expression related to TG and HDL-C
metabolism in the liver of Ldlr/ mice
Hepatic gene expression analysis revealed that K-877 adminis-
tration signiﬁcantly increased the expression of Ppara and its target
genes such as Acox1, Cpt1a, Creb3l3, and Fgf21, which activate fatty
acid oxidation, in the liver of Ldlr/ mice (Fig. 3A). There were no
differences in the hepatic gene expression of the lipoprotein lipase
(LPL) activators Apoa5 and Apoc2 between K-877-treated and un-
treated mice. However, the expression of the LPL inhibitor Apoc3
signiﬁcantly decreased in the liver of K-877-treated Ldlr/ mice
compared with that in the liver of untreated mice (Fig. 3A). These
results suggest that K-877-treated Ldlr/mice have higher plasma
LPL activity than non-treated Ldlr/ mice. To conﬁrm this, we
measured the plasma LPL activity in these mice. K-877 adminis-
tration signiﬁcantly increased the plasma LPL activity compared
with non-treated Ldlr/mice (Fig. 3B). These ﬁndings suggest that
K-877 activates fatty acid oxidation in the liver and plasma LPL
activity, contributing to the decrease in plasma TG levels. The
expression of Abca1 also signiﬁcantly increased in the liver of K-
877-treated Ldlr/ mice (Fig. 3A), contributing to the increase in
plasma HDL-C levels. However, the expression of Apoa1 was un-
changed (Fig. 3A).
3.3. K-877 regulates cholesterol and TG metabolic gene expression
in the small intestine of Ldlr/ mice
K-877 administration to Ldlr/ mice remarkably increased the
expression of Ppara and its target genes such as Creb3l3, Acox1, and
Cpt1a in the small intestine (Fig. 4A). Moreover, K-877 adminis-
tration signiﬁcantly increased the expression of Lxra and Abca1, but
not that of Lxrb, Abcg5, and Apoa1 (Fig. 4A). Conversely, K-877
administration signiﬁcantly reduced Npc1l1 expression in the small
intestine of Ldlr/ mice (Fig. 4A). K-877 administration tended to
reduce the expression of Apob (Fig. 4A). These results suggested
that K-877 induced intestinal fatty acid oxidation and intestinal
HDL-C secretion and reduced cholesterol absorption in theTable 1
Primer sets used for real-time PCR.
Gene name Primer (forward) Primer (reverse)
Abca1 AAAACCGCAGACATCCTTCAG CATACCGAAACTCGTTCACCC
Abcg5 AGGGCCTCACATCAACAGAG GCTGACGCTGTAGGACACAT
Acox1 CGATCCAGACTTCCAACATGAG CCATGGTGGCACTCTTCTTAACA
Apoa1 TCACCCACACCCTTCAGGAT CTGGCTCCCTGTCAGGAAGA
Apoa5 GCGAGTTCTGCCGTAGGAC CCCAACCCCATCAAATGTGA
Apob TTGGCAAACTGCATAGCATCC TCAAATTGGGACTCTCCTTTAGC
Apoc2 CCAAGGAGGTTGCCAAAGAC TGCCTGCGTAAGTGCTCATG
Apoc3 TACAGGGCTACATGGAACAAGC CAGGGATCTGAAGTGATTGTCC
Cpt1a CCTGGAACCTGGCAACTTCAT GGACGCCACTCACGATGTT
Creb3l3 CCTGTTTGATCGGCAGGAC CGGGGGACGATAATGGAGA
Cyclophilin TGGCTCACAGTTCTTCATAACCA ATGACATCCTTCAGTGGCTTGTC
Fgf21 AGATCAGGGAGGATGGAACA TCAAAGTGAGGCGATCCATA
Lxra AGCAACAGTGTAACAGGCGCT ACGATGGCCAGCTCAGTAAAGT
Lxrb ATGTCTTCCCCCACAAGTTCT GACCACGATGTAGGCAGAGC
Npc1l1 ATCCTCATCCTGGGCTTTGC GCAAGGTGATCAGGAGGTTGA
Ppara ACGCGAGTTCCTTAAGAACCTG GTGTCATCTGGATGGTTGCTCTintestine and chylomicron secretion from the intestine. Taken
together, the effect of K-877 on the liver and small intestine
improved lipid metabolism in a mouse model of hyperlipidemia.
To conﬁrm the effects of K-877 on the small intestine of Ldlr/
mice, we determined intestinal and fecal TC levels. Fecal cholesterol
levels signiﬁcantly increased in K-877-treated Ldlr/mice (Fig. 4B).
There were no differences in intestinal TC levels between K-877-
treated and untreated mice (Fig. 4B). These ﬁndings indicated
that K-877 reduces cholesterol absorption in the small intestine of
Ldlr/ mice.
3.4. The effects of K-877 and Feno on intestinal gene expression is
mediated via PPARa
To conﬁrm that the effect of K-877 was mediated by PPARa, WT
and Ppara/mice were treated with Feno (0.2%) or K-877 (0.001%)
for 1 week. There were no apparent differences in the food intake
among all groups (data not shown). The dose of the agonists Feno
(0.2%) and K-877 (0.001%) signiﬁcantly decreased the plasma TG
and TC levels in the treated mice compared with those in the
untreated WT mice, and there were no differences in plasma TG
and TC levels between K-877 and Feno (Takei, submitted data). K-
877 and Feno signiﬁcantly increased the expression of Ppara and
its target genes such as Cpt1a, and Creb3l3 in the small intestine of
WT mice compared with that in the small intestine of untreated
WT mice, and these changes induced by PPARa agonists were
blunted in Ppara/mice (Fig. 5). K-877 signiﬁcantly increased the
expression of Acox1, but Feno did not (Fig. 5). Moreover, K-877
administration had a stronger effect on the expression of these
genes than Feno in spite of the dose differences (Fig. 5). Our
ﬁndings indicated that K-877 more efﬁciently increased the PPARa
transcriptional activity than Feno in the small intestine. K-877 and
Feno signiﬁcantly decreased the expression of Npc1l1 in treated
mice compared with the untreated WT mice; there were no dif-
ferences between K-877 and Feno (Fig. 5). K-877 increased the
expression of Lxra and Abca1, but not that of Lxrb, Abcg5, and Apoa1.
K-877 and Feno administration to Ppara/mice had no detectable
effects on the expression of the genes mentioned above (Fig. 5).
These results indicate that both PPAR agonists have an effective
ability in the small intestine of WT mice and that the functions of
both PPAR agonists are mediated via PPARa.
4. Discussion
In this study, we showed that K-877 administration efﬁciently
induced PPARa activity not only in the liver but also in the small
intestine of Ldlr/ mice. K-877-treated mice had the increased
expression of PPARa and its target genes, i.e., fatty acid oxidation
genes in the liver as well as small intestine. Moreover, K-877
administration signiﬁcantly decreased the expression of Npc1l1,
encoding the rate-limiting transporter for cholesterol absorption,
and with an increase expression of Abca1, which was related to
HDL-C secretion, in the liver and small intestine. These changes
resulted in the reduction in TG and TC levels in plasma and the
increase in plasma HDL-C levels in Ldlr/ mice. Therefore, K-877
administration improved the dysregulation of lipid metabolism in
Ldlr/mice through the increased activity of PPARa in the liver and
small intestine.
Whole body cholesterol homeostasis is maintained by a com-
plex network of biosynthetic, trafﬁcking, secretory, and regulatory
mechanisms.1 Among these mechanisms, the enterohepatic circu-
lation of cholesterol and bile salts plays a critical role.2 For the
maintenance of cholesterol homeostasis in adult organisms, in-
testinal cholesterol absorption and endogenous cholesterol syn-
thesis must be matched by biliary cholesterol and bile acid
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Fig. 2. K-877 reduced plasma triglyceride and total cholesterol levels and increased the plasma HDL cholesterol levels in Ldlr/ mice. (A) Eight-week-old male Ldlr/ mice
were fed MF diets containing K-877 (0.001%) for 1 week. Plasma TG, TC, HDL-cholesterol, and non-esteriﬁed fatty acid (NEFA) levels were measured; n ¼ 8e9 per group; *p < 0.05
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postprandial state may be not only due to the well-established
rapid clearance of TG from circulation due, in part, to an
increased LPL activity6 but also due to the decreased secretion of TG
into circulation from the small intestine.K-877, a highly speciﬁc PPARa-agonist with SPPARMa proper-
ties, has a superior lipid-modifying efﬁcacy at considerably lower
doses in humans with dyslipidemia.31 PPARa is expressed in many
tissues including skeletal muscle, adipose intestine, kidney, and
heart tissues. Recently, liver-speciﬁc PPARa knockout mice were
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PPARa is sufﬁcient to promote hyperlipidemia.32
The lowering effects of plasma TG and TC levels by PPARa
agonists mainly depend on the liver and small intestine. K-877
signiﬁcantly decreased the postprandial TG response, suggesting
that K-877 increases plasma LPL activity and TG absorption from
the small intestine. K-877 efﬁciently increased the expression of
PPARa target genes such as Acox1, Cpt1a, and Creb3l3 in the liver
and small intestine of Ldlr/ mice, thereby activating fatty acid
oxidation in both tissues. Moreover, the activation of intestinal
fatty acid oxidation by the PPARa agonist bezaﬁbrate suppresses
postprandial lipidemia in WT mice.33 Thus, this change in the liverand small intestine could decrease the TG supply for its secretion
into the blood circulation. PPARa activation leads to the stimula-
tion of the catabolism of TG-rich lipoproteins that is caused not
only by the upregulation of plasma LPL activity but also by the
decreased mRNA expression of Apoc3, which has inhibitory effects
on LPL activity.34,35 K-877 administration to Ldlr/ mice
decreased Apoc3 expression. We conﬁrmed that K-877 signiﬁ-
cantly activated plasma LPL activity, which contributes to a
decrease in plasma TG levels. In agreement with previous re-
ports36,37, we conﬁrmed that K-877 increased hepatic Fgf21
expression that results in the amelioration of hyperlipidemia by
inducing lipid catabolism.
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culation, the function of the small intestine is important, particu-
larly for cholesterol absorption from food. NPC1L1 is a rate-limiting
transporter for cholesterol absorption in the small intestine of mice.
A high dose of Feno reduces intestinal cholesterol absorption via
the PPARa-dependent modulation of Npc1l1 expression in mice.22
We showed that a low dose of administrated K-877 correlated
with more efﬁcient reduction of Npc1l1 expression in the small
intestine than a high dose of Feno. However, it remains unknown if
the mouse Npc1l1 promoter has a PPRE sequence, the PPAR-
response element, while it was reported that human NPC1L1 pro-
moter has a PPRE sequence.38 Conversely, human NPC1L1
promoter activity is upregulated by PPARa.38 Thus, there is species
difference between mice and humans in the regulation of the
NPC1L1 expression by PPARa. In addition, there is a difference in
tissue distribution; human NPC1L1 is expressed in the liver and
small intestine, and mouse Npc1l1 is expressed only in the small
intestine. In both species, a PPARa agonist could decrease plasma
cholesterol levels via different mechanisms. In humans, a PPARa
agonist increases NPC1L1 expression in the liver and small intes-
tine. A PPARa agonist efﬁciently transfers the absorbed cholesterol
from the small intestine to the liver, thereby decreasing plasma
cholesterol levels. In contrast, in mice, cholesterol absorption in thesmall intestine decreases in response to a PPARa agonist, thereby
decreasing plasma cholesterol levels. Therefore, although there is
species difference, a PPARa agonist would be a drug for hyper-
cholesterolemia. There is a candidate molecule to regulate mouse
Npc1l1 promoter activity by K-877. Recently, we have reported
that intestinal CREB3L3 overexpression decreases cholesterol ab-
sorption in the small intestine by directly downregulating the
expression of Npc1l1.39 Thus, there is a possibility that K-877-
induced CREB3L3 expression contributes to the regulation of
Npc1l1 expression. Ezetimibe, an inhibitor for NPC1L1, decreased
the absorption of intestinal cholesterol and Abca1 and Abcg5
expression but had no inﬂuence on the levels of serum HDL-C or
ApoA-I.40 Thus, K-877 could be the most efﬁcient drug to improve
lipid metabolism. Feno increases plasma HDL-C levels in Ldlr/
mice only when human ApoA-I is overexpressed in these animals.41
GW7647, a PPARa agonist, has no effect on the lipoprotein proﬁle in
Ldlr/ mice fed an atherogenic diet.42 Thus, K-877 is a promising
drug for improving lipid proﬁle in Ldlr/ mice. ABCA1 is an
important molecule to produce HDL-C by transporting intracellular
cholesterol from the liver and small intestine. Intestinal ABCA1
deﬁciency leads to deﬁcient HDL biogenesis, thereby reducing
cholesterol inﬂux into the circulation.10,43 Feno and Wy14643 in-
crease Abca1 expression in the small intestine.18 In this study, K-877
K. Takei et al. / Journal of Pharmacological Sciences 133 (2017) 214e222 221apparently increased Abca1 expression in WT mice, but Feno did
not. Our data indicate that K-877 more efﬁciently works in the
small intestine in comparison with Feno. Similar to the Npc1l1
promoter, it remains unknown if the mouse Abca1 promoter has a
PPRE sequence. A previous report showed that PPARa agonist-
induced Abca1 expression is mediated by LXRs.18 The increase in
Abca1 expression by K-877 was blunted in Ppara/ mice. K-877
slightly increased the expression of LXRa expression but not that of
LXRb. The mouse LXRa promoter has a PPRE consensus sequence.44
Therefore, K-877 partially increases Abca1 expression via PPARa-
induced LXR activation.
To conclude, we reported that K-877 administration reduced
plasma TG and TC levels and increased plasma HDL-C levels in
Ldlr/mice. K-877 administration regulated hepatic and intestinal
fatty acid oxidation and apolipoprotein mRNA expression, thereby
reducing plasma TG levels. K-877 administration remarkably
reduced Npc1l1 expression and increased Abca1 expression in the
small intestine. These data clearly showed that K-877, acting via
PPARa, reduced cholesterol absorption in part by altering the in-
testinal expression of Npc1l1. K-877 administration increased he-
patic and intestinal Abca1 expression, contributing to an increase in
plasma HDL-C levels. Selective activation of PPARa by K-877 in the
small intestine was associated with beneﬁcial changes in choles-
terol metabolism genes, suggesting the potential of this novel agent
in treating cardiovascular diseases.
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